FDA should schedule regs for revision "semi-annually" -- PhRMA comments on "ReGo".
This article was originally published in The Tan Sheet
Executive Summary
FDA REG "SEMI-ANNUAL" REVIEW RECOMMENDED BY PhRMA in Aug. 30 comments on the advanced notice of proposed rulemaking in the June 4 Federal Register covering the agency's "Reinventing Government" initiatives. The Pharmaceutical Research & Manufacturers of America urged FDA to "develop, adopt and publish a plan for periodic review of all portions of its regulations." As an example, PhRMA suggested that the agency "publish semi-annually a list of sections of the [Code of Federal Regulations] scheduled to be reviewed and revised within the next six months and in the subsequent six-month period."